Cellular Immunotherapy for Cervical Cancer: Next Therapeutics Frontiers

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Advanced cervical cancer necessitates innovative therapeutic strategies.
• Human Papillomavirus (HPV) oncoproteins (E6/E7) serve as effective tumor-specific antigens for cellular immunotherapy.
• Current research focuses on four main immunotherapy platforms.

Purpose of the Study:

• To systematically review and analyze key cellular immunotherapy platforms for cervical cancer.
• To evaluate the preclinical basis, clinical progress, safety, and manufacturing hurdles of each approach.
• To identify future directions for enhancing therapeutic efficacy and accessibility.

Main Methods:

• Systematic review of tumor-infiltrating lymphocytes (TILs), TCR-engineered T cells, CAR-T cells, and CAR-NK cells.
• Analysis of preclinical data, clinical trial outcomes, safety profiles, and manufacturing considerations.
• Critical evaluation of current challenges and future engineering strategies.

Main Results:

• TIL therapy has demonstrated durable responses and received FDA Breakthrough Therapy designation.
• TCR-T cells offer precise targeting but are limited by HLA restriction.
• CAR-T cells provide MHC-independent targeting but face toxicity and tumor microenvironment challenges.
• CAR-NK cells exhibit a favorable safety profile and potential for off-the-shelf application.

Conclusions:

• Combination strategies and next-generation engineering (e.g., armored CARs, allogeneic platforms) are crucial for overcoming current limitations.
• Addressing manufacturing complexity, toxicity, and cost is essential for broader clinical adoption.
• Expanding these advanced therapies to resource-limited settings is critical given the high cervical cancer burden.